Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party

Journal of Clinical Oncology

Volumn 25, Issue 31, 2007, Pages 4938-4945

  Schmid, Christoph ^a   Labopin, Myriam ^b   Nagler, Arnon ^b   Bornhäuser, Martin ^b   Finke, Jürgen ^b   Fassas, Athanasios ^b   Volin, Liisa ^b   Gürman, Günham ^b   Maertens, Johan ^b   Bordigoni, Pierre ^b   Holler, Ernst ^b   Ehninger, Gerhard ^b   Polge, Emmanuelle ^b   Gorin, Norbert Claude ^b   Kolb, Hans Jochem ^b   Rocha, Vanderson ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; FOLLOW UP; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 36849048316     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.6053     Document Type: Article

References (36)

1. Kolb HJ, Mittermuller J, Clemm C, et al: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462-2465, 1990
2. Collins RH Jr, Rogers ZR, Bennett M, et al: Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: Apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 10:391-395, 1992
3. Mackinnon S, Papadopoulos EB, Carabasi MH, et al: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86:1261-1268, 1995
4. Kolb HJ, Schattenberg A, Goldman JM, et al: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041-2050, 1995
5. Porter DL, Roth MS, Lee SJ, et al: Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 18:975-980, 1996
6. Collins RH Jr, Shpilberg O, Drobyski WR, et al: Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997
7. Levine JE, Braun T, Penza SL, et al: Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol 20:405-412, 2002
8. Sullivan KM: Graft-versus-host-disease, in Thomas E, Blume K, Forman SJ, (eds): Hematopoietic Cell Transplantation (ed 2). Boston, MA, Blackwell Science, 1999, pp 515-536
9. Kaplan E, Meier P: Non parametric estimation from incomplete observatinons. J Am Stat Assoc 53:457-481, 1958
10. Cox DR: Regression models and life tables. J R Stat Soc 34:187-202, 1972
11. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075-4083, 2000
12. Aoudjhane M, Labopin M, et al: Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: A retrospective survey ofrom the Acute Leukaemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 19:2304-2312, 2005
13. Frassoni F, Barrett AJ, Granena A, et al: Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the E.B.M.T. of 117 cases. Br J Haematol 70:317-320, 1988
14. Mortimer J, Blinder MA, Schulman S, et al: Relapse of acute leukemia after marrow transplantation: Natural history and results of subsequent therapy. J Clin Oncol 7:50-57, 1989
15. Radich JP, Sanders JE, Buckner CD, et al: Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 11:304-313, 1993
16. Barrett AJ, Locatelli F, Treleaven JG, et al: Second transplants for leukaemic relapse after bone marrow transplantation: High early mortality but favourable effect of chronic GVHD on continued remission: A report by the EBMT Leukaemia Working Party. Br J Haematol 79:567-574, 1991
17. Michallet M, Tanguy ML, Socie G, et al: Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: A survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 108:400-407, 2000
18. Eapen M, Giralt SA, Horowitz MM, et al: Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 34:721-727, 2004
19. Bosi A, Laszlo D, Labopin M, et al: Second allogeneic bone marrow transplantation in acute leukemia: Results of a survey by the European Cooperative Group fpr Blood and Marrow Transplantation. J Clin Oncol 19:3675-3684, 2001
20. Hosing C, Saliba RM, Shahjahan M, et al: Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant 36:157-162, 2005
21. Zittoun RA, Mandelli F, Willemze R, et al: Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia: European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217-223, 1995
22. Cassileth PA, Harrington DP, Appelbaum FR, et al: Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998
23. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
24. Larson RA, Sievers EL, Stadtmauer EA, et al: Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotagr) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104:1442-1452, 2005
25. Taksin AL, Legrand O, Raffoux E, et al: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alpha group. Leukemia 21:66-71, 2007
26. Platzbecker U, Thiede C, Freiberg-Richter J, et al: Treatment of relapsing leukemia after allogeneic blood stem cell transplantation by using dose-reduced conditioning followed by donor blood stem cells and GM-CSF. Ann Hematol 80:144-149, 2001
27. Choi SJ, Lee JH, Lee JH, et al: Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: A high incidence of isolated extramedullary relapse. Leukemia 18:1789-1797, 2004
28. Slavin S, Naparstek E, Nagler A, et al: Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 87:2195-2204, 1996
29. Schmid C, Schleuning M, Aschan J, et al: Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation. Leukemia 18:1430-1433, 2004
30. Arellano ML, Langston A, Winton E, et al: Treatment of relapsed acute myeloid leukemia after allogeneic transplantation: A single center experience. Biol Blood Marrow Transplant 13:116-123, 2007
31. Kolb HJ, Rank A, Chen X, et al: In-vivo generation of leukaemia-derived dendritic cells. Best Pract Res Clin Haematol 17:439-451, 2004
32. Porter DL, Levine BL, Bunin N, et al: A phase I trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD38 costimulation. Blood 107:1325-1331, 2006
33. Pawson R, Potter MN, Theocharous P, et al: Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +-/- Ida) and second allogeneic stem cell transplant. Br J Haematol 115:622-629, 2001
34. de Lima M, Bonamino M, Vasconcelos Z: Prophylactic donor lymphocyte transfusion after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: High remission rate at the expense of of graft-versus-host disease. Bone Marrow Transplant 27:73-78, 2001
35. Massenkeil G, Nagy M, Lawang M: Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved. Bone Marrow Transplant 31:339-345, 2003
36. Schmid C, Schleuning M, Ledderose G, et al: Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675-5687, 2005